- Home
- REKR vs SPRO Comparison
REKR vs SPRO Comparison
Compare REKR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REKR
- SPRO
- Stock Information
- Founded
- REKR 2017
- SPRO 2013
- Country
- REKR United States
- SPRO United States
- Employees
- REKR N/A
- SPRO N/A
- Industry
- REKR Telecommunications Equipment
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- REKR Telecommunications
- SPRO Health Care
- Exchange
- REKR Nasdaq
- SPRO Nasdaq
- Market Cap
- REKR 153.5M
- SPRO 162.1M
- IPO Year
- REKR N/A
- SPRO 2017
- Fundamental
- Price
- REKR $1.23
- SPRO $2.66
- Analyst Decision
- REKR
- SPRO Buy
- Analyst Count
- REKR 0
- SPRO 4
- Target Price
- REKR N/A
- SPRO $5.00
- AVG Volume (30 Days)
- REKR 3.8M
- SPRO 1.2M
- Earning Date
- REKR 08-13-2025
- SPRO 08-04-2025
- Dividend Yield
- REKR N/A
- SPRO N/A
- EPS Growth
- REKR N/A
- SPRO N/A
- EPS
- REKR N/A
- SPRO N/A
- Revenue
- REKR $45,448,000.00
- SPRO $44,584,000.00
- Revenue This Year
- REKR $8.68
- SPRO N/A
- Revenue Next Year
- REKR $21.45
- SPRO N/A
- P/E Ratio
- REKR N/A
- SPRO N/A
- Revenue Growth
- REKR 17.97
- SPRO N/A
- 52 Week Low
- REKR $0.62
- SPRO $0.51
- 52 Week High
- REKR $2.67
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- REKR 51.85
- SPRO 60.75
- Support Level
- REKR $1.19
- SPRO $2.89
- Resistance Level
- REKR $1.30
- SPRO $3.22
- Average True Range (ATR)
- REKR 0.08
- SPRO 0.13
- MACD
- REKR -0.00
- SPRO -0.07
- Stochastic Oscillator
- REKR 57.69
- SPRO 12.64
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.